MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASSTM (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET[1] imaging agents, Illuccix® (kit [...]The post First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study appeared first on Australian Business Announcements .
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
